Dual effects of rifampin on the pharmacokinetics of atrasentan

Journal of Clinical Pharmacology

Volumn 47, Issue 4, 2007, Pages 423-429

  Xiong, Hao ^a   Carr, Robert A ^a   Locke, Charles S ^a   Katz, David A ^a   Achari, Ramanuj ^a   Doan, Thao T ^a   Wang, Perry ^a   Jankowski, James R ^a   Sleep, Darryl J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Atrasentan; Cytochrome P450 3A; Drug interaction; Organic anion transporting polypeptide; Rifampin

Indexed keywords

ANION; ATRASENTAN; CYTOCHROME P450; POLYPEPTIDE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG UPTAKE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN;

ADULT; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; ENZYME INDUCTION; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RIFAMPIN;

EID: 33947511156     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007299928     Document Type: Article

References (23)

1. Herrmann E., Bogemann M., Bierer S., Eltze E., Hertle L., Wulfing C. The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications. Expert Rev Anticancer Ther. 2006 ; 6: 73-81.
2. Jimeno A., Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther. 2005 ; 5: 419-427.
3. Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol. 2002 ; 20: 2171-2180.
4. Ryan CW, Vogelzang NJ, Vokes EE, et al. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 ; 10: 4406-4411.
5. Zonnenberg BA, Groenewegen G., Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res. 2003 ; 9: 2965-2972.
6. Jimeno A., Carducci M. Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opin Investig Drugs. 2004 ; 13: 1631-1640.
7. Food and Drug Administration (FDA). Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis and Recommendations for Dosing and Labeling. Rockville, Md: US Department of Health and Human Services, Food and Drug Administration ; 1999.
8. Wang PG, Wei J., Chang M., El-Shourbagy T. High-throughput determination of atrasentan in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Biomed Chromatogr. 2005 ; 19: 663-670.
9. Katz DA, Carr R., Grimm DR, et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 ; 79: 186-196.
10. Rae JM, Johnson MD, Lippman ME, Flockhart DA Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001 ; 299: 849-857.
11. Xie W., Yeuh MF, Radominska-Pandya A., et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA. 2003 ; 100: 4150-4155.
12. Tirona RG, Leake BF, Wolkoff AW, Kim RB Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 ; 304: 223-228.
13. Vavricka SR, Van Montfoort J., Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 ; 36: 164-172.
14. Polk RE, Brophy DF, Israel DS, et al. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother. 2001 ; 45: 502-508.
15. Bidstrup TB, Stilling N., Damkier P., Scharling B., Thomsen MS, Brøsen K. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol. 2004 ; 60: 109-114.
16. Hatorp V., Hansen KT, Thomsen MS Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol. 2003 ; 43: 649-660.
17. Niemi M., Backman JT, Neuvonen M., Neuvonen PJ, Kivistö KT Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther. 2000 ; 68: 495-500.
18. Niemi M., Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 ; 77: 468-478.
19. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004 ; 75: 455-463.
20. Shitara Y., Itoh T., Sato H., Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 2003 ; 304: 610-616.
21. Treiber A., Schneiter R., Delahaye S., Clozel M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther. 2004 ; 308: 1121-1129.
22. Kajosaari LI, Niemi M., Neuvonen M., Laitila J., Neuvonen PJ, Backman JT Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005 ; 78: 388-399.
23. Niemi M., Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003 ; 42: 819-850.